Abstract：【Objective】 To investigate the relationship between circulating endothelial progenitor cells (EPCs) and plasma stromal cell-derived factor-1α(SDF-1α). 【Methods】 A total of 153 patients with TIA within 24 hours were collected and divided into high-risk TIA group (83 cases) and non high-risk TIA group (70 cases). The clinical data of patients were collected, the number of circulating EPCs was measured by flow cytometry, and the concentration of plasma SDF-1αand vascular endothelial growth factor (VEGF) was measured by enzyme-linked immunosorbent assay . 15 healthy volunteers were selected as normal control (NC). According to the time of admission, the circulating EPCs of the top 15 patients in the high-risk TIA group and the non high-risk TIA group were collected. The proliferation ability of circulating EPCs in the three groups was measured by MTT method, and the migration ability of EPCs was measured by Boyden chamber. 【Results】 Compared with the non high-risk group TIA, the high-risk group TIA had a higher age, and more patients with hypertension and diabetes, and three triglycerides, total cholesterol and low density lipoprotein in peripheral blood were also higher. There was no significant difference in smoking, body mass index and homocysteine between the two groups (P>0.05). Circulating EPCs, SDF-1α and VEGF in the non high risk TIA group was higher than that in the high-risk TIA group (P<0.01). Multivariate regression analysis showed that age, hypertension, diabetes, total cholesterol, SDF-1αand EPCs were high-risk TIA risk factors, and EPCs were high-risk TIA protective factors. Compared with the NC group, the proliferation and migration ability of EPCs isolated and cultured for 72 hours in the high-risk TIA group and the non high-risk TIA group decreased (P<0.05). Compared with the non high-risk TIA group, the proliferation and migration of cells in the high-risk TIA group decreased (P<0.01). 【Conclusion】 The level of circulating EPCs and plasma SDF-1αmay be used as an index to evaluate the severity of TIA. The decline of proliferation and migration ability of circulating EPCs may lead to high-risk TIA.
[1] WANG Y,ZHAO X,JIANG Y,et al. Prevalence,knowledge,and treatment of transient ischemic attacks in China[J].Neurology,2015,84(23):2354-2361. [2] WANG Y, LI Z, ZHAO X,et al. Stroke care quality in china: substantial improvement, and a huge challenge and opportunity[J].Int J Stroke,2017,12(3):229-235. [3] ULVI BAYRAKTUTAN. Endothelial progenitor cells: Potential novel therapeutics for ischaemic stroke[J].Pharmacol Res,2019,144(6):181-191. [4] HUANG X. The stromal cell-derived factor-1α(SDF-1α)/cysteine-X-cysteine chemokine receptor 4 (CXCR4) axis: a possible prognostic indicator of acute ischemic stroke[J].J Int Med Res,2019,47(5):1897-1907. [5] DENG Y, WANG J, HE G,et al. Mobilization of endothelial progenitor cell in patients with acute ischemic stroke[J].Neurol Sci,2018,39(3):437-443. [6] MEAMAR R, NIKYAR H, DEHGHANI L, et al. The role of endothelial progenitor cells in transient ischemic attack patients for future cerebrovascular events[J].J Res Med Sci,2016,21(6):47-52. [7] MAREK KUKUMBERG , AUNG MOE ZAW , DANIEL H C WONG,et al.Characterization and functional assessment of endothelial progenitor cells in ischemic stroke patients [J].Stem Cell Rev Rep,2020,11(10):1-16. [8] ASAHARA T,KAWAMOTO A. Endothelial progenitor cells for postnatal vasculogenesis[J].Am J Physiol Cell Physiol,2004, 287(3): C572-C579. [9] XUE L. Changes in serum vascular endothelial growth factor and endostatin concentrations associated with circulating endothelial progenitor cells after acute ischemic stroke[J].Metab Brain Dis,2017,32(2):641-648. [10] ZAMANI P, FEREYDOUNI N, BUTLER A E,et al.The therapeutic and diagnostic role of exosomes in cardiovascular diseases [J].Trends Cardiovasc Med,2019,29(6):313-323. [11] GEMA ESQUIVA, ALBA GRAYSTON, ANNA ROSELL. Revascularization and endothelial progenitor cells in stroke[J].Am J Physiol Cell Physiol,2018,315(5):C664-C674. [12] FRANCESCO PELLICCIA, VINCENZO PASCERI, ANDREA MORETTI,et al. Endothelial progenitor cells predict long-term outcome in patients with coronary artery disease: Ten-year follow-up of the PROCREATION extended study[J].Int J Cardiol,2020,318(11):123-125. [13] MARK D ROSS. Endothelial regenerative capacity and aging: influence of diet, exercise and obesity[J].Curr Cardiol Rev,2018,14(4):233-244. [14] MAKINO H,MIYAMOTO Y, KIKUCHI-TAURA A,et al. Decreased levels of circulating CD34+ cells are associated with coronary heart disease in Japanese patients with type 2 diabetes[J].J Diabetes Investig,2015,6 (4):473-478. [15] CHEN Y,LU B,WANG J,et al. Circulating CD133+ CD34+ progenitor cells and plasma stromal-derived factor-1alpha: predictive role in ischemic stroke patients[J].J Stroke Cerebrovasc Dis,2015,24(2):319-326. [16] XUAN CHENG,YA-JUN LIAN,YUN-QING MA,et al.Elevated serum levels of CXC chemokine ligand-12 are associated with unfavorable functional outcome and mortality at 6-month follow-up in chinese patients with acute ischemic stroke[J].Mol Neurobiol,2017,54(2):895-903. [17] GOLAB-JANOWSKA M, PACZKOWSKA E, MACHALINSKI B, et al.Statins therapy is associated with increased populations of early endothelial progenitor (CD133+/VEGFR2+) and endothelial (CD34-/CD133-/VEGFR2+) cells in patients with acute ischemic stroke[J].Curr Neurovasc Res,2018,15(2):120-128. [18] ESQUIVA G, GRAYSTON A, ROSELL A. Revascularization and endothelial progenitor cells in stroke [J].Am J Physiol Cell Physiol,2018,315(5):C664-C674. [19] PAN Y, CHEN W, WANG Y,et al.Association between ABCB1 polymorphisms and outcomes of clopidogrel treatment in patients with minor stroke or transient ischemic attack: secondary analysis of a randomized clinical trial [J].JAMA Neurol,2019,76(5):552-560. [20] DAOUSSI NIZAR, MSOLLI M AMINE, MOUNA AISSI,et al. External validations of the ABCD2 score in prediction of stroke risk after transient ischemic attack:a tunisian hospital-based cohort study[J].Int J Neurosci,2020,16(10):1-7. [21] ZHANG L, LI X, WANG D,et al. Risk factors of recurrent ischemic events after acute noncardiogenic ischemic stroke [J].Curr Pharm Des,2019,25(45):4827-4834. [22] HURFORD R, WOLTERS FJ, LI L, et al . Prognosis of asymptomatic intracranial stenosis in patients with transient ischemic attack and minor stroke[J].JAMA Neurol,2020,77(8):947-954. [23] LI J. Soluble CD40L is a useful marker to predict future strokes in patients with minor stroke and transient ischemic attack[J].Stroke,2015,46(7):1990-1992. [24] KELLY PJ, ALBERS GW, CHATZIKONSTANTINOU A, et al. Validation and comparison of imaging-based scores for prediction of early stroke risk after transient ischaemic attack: a pooled analysis of individual-patient data from cohort studies[J].Lancet Neuro,2016,15(12):1238-1247.
2021, Vol. 38 
